Analysts of Jefferson Research are encouraged by Valeant's recent projections, citing strong earnings quality and balance quality; however, the valuation suggests a lower amount of price risk in addition to weak cash flow quality and operating efficiency. Future drugs to keep an eye on include Relistor Oral, Vyzulta, and Siliq.